CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas

Inclusion Criteria: * Histologically confirmed supratentorial Diffuse low-grade and intermediate-grade gliomas (World Health Organization grades II and III ) * IDH wild-type and TERT promoter mutation * Age \> 18 * Karnofsky performance score \> 60 * Neutrophilic granulocyte count \> 1500/µl * Platelet count \> 100 000/µl * Hemoglobin \> 10 g/dl * Serum creatinine \< 1.5 times the lab's upper normal limit * AST or ALT \< 1.5 times the lab's upper normal limit * Adequate medical health to participate in this study * No previous systemic chemotherapy * No previous radiotherapy to the brain * Written informed consent Exclusion Criteria: * Serious medical or neurological condition with a poor prognosis * Contraindications to radiotherapy or temozolomide chemotherapy * Patient unable to follow procedures, visits, examinations described in the study * Second cancer requiring radiotherapy or chemotherapy * Inability to undergo gadolinium-contrasted MRIs * Pregnant women or nursing mothers can not participate in the study